31/03/2017
Asarina Pharma's phase IIa clinical study with Sepranolone in premenstrual dysphoric disorder meets primary endpoint
Asarina Pharma, a drug development company focusing on the development of a novel therapy for severe premenstrual symptoms, publishes the efficacy and safety data from the randomized, controlled trial involving a total of 120 women with PMDD, in Psychoneuroendocrinology. [...]
